Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | C1S | P09871 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | AGXT | P21549 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12353999 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPK1KDM1AC1SPARP1 | |
| SCHEMBL1966415 | 0.81 | KDM1A (0.48) | KDM1AAKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL816335 | 0.73 | PDE2A (0.32) | WDR5TDP1 | |
| SCHEMBL15108851 | 0.72 | ACHE (0.44) | MAPK1KDM1AAKR1C3AKR1C2PARP1 | |
| SCHEMBL4620762 | 0.71 | CYP2A6 (0.50) | ALDH1A1WDR5 | |
| SCHEMBL5000 | 0.71 | — | — | |
| SCHEMBL25037230 | 0.70 | ALDH1A1 (0.42) | ALDH1A1KDM1AAKR1C3AKR1C2PARP1 | |
| SCHEMBL1633970 | 0.70 | CYP3A4 (0.52) | ALDH1A1MAPK1KDM1AAKR1C3AKR1C2 | |
| SCHEMBL1635377 | 0.70 | KDM1A (0.41) | KDM1AAKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL816860 | 0.70 | ACHE (0.52) | ALDH1A1MAPK1KDM1AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102224147-B | Process for preparing poly (pentafluorosulfanyl) aromatic compounds | UBE INDUSTRIES | 2015-03-18 | — | — | CN | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4665717-A2 | USES OF CERTAIN 1,4-OXAZEPANE-2-CARBOXAMIDES AS DPP1 INHIBITORS | Insmed Incorporated (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250353828-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4570800-A1 | CRYSTAL FORM OF PYRIDINOPYRIMIDINONE COMPOUND, ACID SALT THEREOF, CRYSTAL FORM OF ACID SALT THEREOF, AND USE | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-06-18 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4536639-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | Oregon Health & Science University (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119487038-A | KRAS G12D modulating compounds | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-7592491-B2 | Process for producing arylsulfur pentafluorides | IM&T RESEARCH, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592491-B2 | Process for producing arylsulfur pentafluorides | IM&T RESEARCH, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| CN-101475519-A | Method for producing 4-pentafluoride-sulfanyl-benzoylguanidines | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-08 | — | — | CN | disclosed |
| CN-100480237-C | Process for preparing 4-pentafluorosulfanylbenzoylguanidines | AVENTIS PHARMA GMBH (DE) | 2009-04-22 | — | — | CN | disclosed |
| CN-100445265-C | Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same | AVENTIS PHARMA GMBH (DE) | 2008-12-24 | — | — | CN | disclosed |
| US-20080234520-A1 | PROCESS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES | IM&T RESEARCH, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234520-A1 | PROCESS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES | IM&T RESEARCH, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| CN-1878753-A | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | AVENTIS PHARMA GMBH (DE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1878754-A | Process for preparing 4-pentafluorosulfanylbenzoylguanidines | AVENTIS PHARMA GMBH (DE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1878755-A | Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same | AVENTIS PHARMA GMBH (DE) | 2006-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353828-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | EPX, TFEB, EPHX1 | ALDH1A1 2498/4885MAPK1 4158/4885KDM1A 2980/4885 |
| US-20080234520-A1 | PROCESS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES | PFAS, MPST, ARSA | ALDH1A1 2190/4885MAPK1 794/4885KDM1A 4556/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | ALDH1A1 4238/4885MAPK1 2543/4885KDM1A 4149/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | ALDH1A1 4457/4885MAPK1 3342/4885KDM1A 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.